Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) — The “Global Next Generation Immunotherapies Market (2023-2028) by Drug Class, Route of Administration, Distribution Channel, and Geography, Competitive Analysis, Impact of Covid-19, Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
The Global Next Generation Immunotherapies Market was estimated at USD 112.78 Billion in 2023 and is expected to reach USD 162.66 Billion by 2028, growing at a CAGR of 7.60%.
The Global Next Generation Immunotherapies Market is segmented based on Drug Class, Route of Administration, Distribution Channel, and Geography.
Monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to mimic the immune system’s ability to fight off harmful pathogens. In next-generation immunotherapies, mAbs are pivotal in targeting specific cells or proteins involved in diseases, including cancer and autoimmune disorders. Monoclonal antibodies offer precision targeting by binding to specific antigens on the surface of cells. This targeted approach minimizes damage to healthy cells and enhances the therapeutic efficacy of the treatment. Monoclonal antibodies have a versatile application across various therapeutic areas, including oncology, rheumatology, and infectious diseases. Their adaptability contributes to the broad spectrum of conditions that next-generation immunotherapies can address. Some monoclonal antibodies have immunomodulatory effects, influencing the body’s immune response. This property is particularly relevant in cancer treatment, where mAbs can enhance the immune system’s ability to recognize and attack cancer cells.
Antibody-drug conjugates (ADCs) represent a class of next-generation immunotherapies that combine the specificity of monoclonal antibodies with the cytotoxic properties of chemotherapy drugs. ADCs aim to deliver therapeutic agents directly to cancer cells, minimizing damage to surrounding healthy tissue. ADCs provide targeted drugs by attaching a potent cytotoxic drug to a monoclonal antibody. This targeted approach enhances the concentration of the drug at the site of action, improving therapeutic efficacy while reducing systemic toxicity. ADCs contribute to the paradigm of precision medicine by tailoring treatment to the specific molecular characteristics of cancer cells. This approach is particularly valuable in treating heterogeneous cancers, where different patients may respond differently to standard therapies. Despite the promise of ADCs, challenges such as drug resistance and the potential for off-target effects exist. Ongoing research and innovations aim to address these challenges by developing new linker technologies and improved payloads to enhance ADC safety and efficacy.
Company Profiles
The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies’ recent development and competitive scenario.
Some of the companies covered in this report are:
- AstraZeneca
- Avantor, Inc.
- Boehringer Ingelheim
- Bristol Myers Squibb
- Huabo Biopharm
- IMBiologics
- ImmunAbs
- MacroGenics
- Mereo BioPharma
- Novacell Technology Inc.
- Pall Corporation
- Regeneron Pharmaceuticals
- Sigma-Aldrich
Competitive Quadrant
The report includes the Competitive Quadrant, a proprietary tool to analyse and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Report Highlights
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 210 |
| Forecast Period | 2023 – 2028 |
| Estimated Market Value (USD) in 2023 | $112.78 Billion |
| Forecasted Market Value (USD) by 2028 | $162.66 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/nypmb6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Next Generation Immunotherapies Market
